Mire-Sluis A R, Das R G, Padilla A
Division of Immunobiology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.
J Immunol Methods. 1998 Jul 1;216(1-2):103-16. doi: 10.1016/s0022-1759(98)00073-8.
The development and widespread application of recombinant DNA technology has dramatically increased the number of cytokines available for clinical evaluation. New and novel cytokines are being discovered, cloned and entered into clinical trials at such a rate that it is often the case that the biological activities of these proteins are poorly understood during their development as therapeutic agents. In addition, manufacturers of any one cytokine can produce the protein from different cellular sources resulting in materials that exhibit markedly different specific activities. When estimating the amount of biological activity of different preparations with different specific activities by bioassay, mass units cannot be used and biological activity is therefore expressed as 'biological potency units'. The biological unit requires definition by a standard that is assay-independent (especially when measuring a particular type of biological activity). In many cases, a variety of assay methods will be available and the material chosen for a standard should ideally be suitable for use with as many of them as possible. Once the unit is defined, this can be used in any laboratory, thus providing a means of ensuring uniformity throughout the world in the designation of potency of different biological preparations. The World Health Organisation (WHO) standardization programme involves the production of biologically stable, well characterised potency and immunoassay standards that are available world-wide using a single international unitage. Over the years, WHO international standards have been used to dramatically reduce the variation in estimates of cytokine preparations within and between laboratories for immunoassays and bioassays. WHO international standards are primary reference preparations against which secondary, or working standards (including regional standards, national standards, pharmacopoeial standards and in-house working standards) can be calibrated.
重组DNA技术的发展与广泛应用极大地增加了可用于临床评估的细胞因子数量。新的和新颖的细胞因子正以如此之快的速度被发现、克隆并进入临床试验,以至于在这些蛋白质作为治疗剂的研发过程中,其生物学活性往往未被充分了解。此外,任何一种细胞因子的制造商都可以从不同的细胞来源生产该蛋白质,从而导致产品具有明显不同的比活性。当通过生物测定法估计具有不同比活性的不同制剂的生物活性量时,不能使用质量单位,因此生物活性表示为“生物效价单位”。生物单位需要通过与测定方法无关的标准来定义(特别是在测量特定类型的生物活性时)。在许多情况下,会有多种测定方法可供使用,理想情况下,选择作为标准的材料应适用于尽可能多的测定方法。一旦定义了单位,就可以在任何实验室中使用,从而提供一种确保世界各地不同生物制剂效价指定一致性的方法。世界卫生组织(WHO)的标准化计划包括生产具有生物稳定性、特征明确的效价和免疫测定标准品,这些标准品可在全球范围内使用单一国际单位制获得。多年来,WHO国际标准已被用于大幅减少免疫测定和生物测定中实验室内部和实验室之间细胞因子制剂估计值的差异。WHO国际标准是一级参考制剂,二级或工作标准品(包括区域标准品、国家标准品、药典标准品和内部工作标准品)可据此进行校准。